Form 4: Travere Therapeutics CRO Sells Shares After Option Exercise

Travere Therapeutics' Chief Research Officer, William E. Rote, exercised stock options and subsequently sold 60,000 shares of common stock for a profit, as detailed in a recent SEC Form 4 filing.

Summary

• William E. Rote, Chief Research Officer of Travere Therapeutics, Inc. (TVTX), reported transactions involving the company's common stock.
• On December 24, 2025, Rote exercised an employee stock option to acquire 60,000 shares of common stock at an exercise price of $20.61 per share.
• Concurrently, Rote sold 60,000 shares of common stock at a weighted average price of $40.103 per share, with prices ranging from $38.00 to $42.07.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on May 29, 2025.
• The stock option was granted on February 13, 2017, and is fully vested and exercisable, with an expiration date of February 13, 2027.
• Following these transactions, Rote beneficially owns 101,443 shares of Travere Therapeutics common stock.
• The reported beneficial ownership also includes 607 shares acquired on May 30, 2025, and 595 shares acquired on November 28, 2025, through the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: This is a routine insider transaction (exercise and sell) executed under a pre-arranged 10b5-1 plan. It reflects a personal financial decision by an officer and does not inherently indicate positive or negative sentiment about the company's future prospects beyond the officer realizing value from vested options.

Positives

• The Chief Research Officer realized a significant profit by exercising options at $20.61 and selling shares at a weighted average price of $40.103.
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating a structured approach to insider trading and reducing concerns about opportunistic selling.

Negatives

• A high-ranking officer sold a substantial number of shares (60,000), which could be interpreted as a reduction in direct equity exposure.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal direct impact on shareholders, as it's a pre-planned personal financial event.

Key Dates

Keywords

Travere Therapeutics, TVTX, William E. Rote, Form 4, insider transaction, stock option, equity sale, Rule 10b5-1, Chief Research Officer, beneficial ownership